CN117529476A - 取代的1,2-二氨基杂环化合物衍生物的制备及其作为药剂的用途 - Google Patents

取代的1,2-二氨基杂环化合物衍生物的制备及其作为药剂的用途 Download PDF

Info

Publication number
CN117529476A
CN117529476A CN202280041809.1A CN202280041809A CN117529476A CN 117529476 A CN117529476 A CN 117529476A CN 202280041809 A CN202280041809 A CN 202280041809A CN 117529476 A CN117529476 A CN 117529476A
Authority
CN
China
Prior art keywords
alkyl
cancer
group
mmol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280041809.1A
Other languages
English (en)
Chinese (zh)
Inventor
白基宣
具滋奕
崔珣奎
朴永焕
西蒙·沃德
达伦·勒格兰德
瑞安·韦斯特
佩内洛普·特纳
萨穆埃莱·马拉迈
特里斯坦·勒永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yafei Luosi Pharmaceutical Co
Original Assignee
Yafei Luosi Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yafei Luosi Pharmaceutical Co filed Critical Yafei Luosi Pharmaceutical Co
Publication of CN117529476A publication Critical patent/CN117529476A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202280041809.1A 2021-06-09 2022-06-09 取代的1,2-二氨基杂环化合物衍生物的制备及其作为药剂的用途 Pending CN117529476A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108249.0A GB202108249D0 (en) 2021-06-09 2021-06-09 Compounds
GB2108249.0 2021-06-09
PCT/KR2022/008105 WO2022260441A1 (en) 2021-06-09 2022-06-09 Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents

Publications (1)

Publication Number Publication Date
CN117529476A true CN117529476A (zh) 2024-02-06

Family

ID=76838874

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280041809.1A Pending CN117529476A (zh) 2021-06-09 2022-06-09 取代的1,2-二氨基杂环化合物衍生物的制备及其作为药剂的用途

Country Status (10)

Country Link
US (1) US20240300936A1 (https=)
EP (1) EP4352049A4 (https=)
JP (1) JP2024522201A (https=)
KR (1) KR20240006692A (https=)
CN (1) CN117529476A (https=)
AU (1) AU2022291332A1 (https=)
CA (1) CA3216629A1 (https=)
GB (1) GB202108249D0 (https=)
MX (1) MX2023014784A (https=)
WO (1) WO2022260441A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250096877A (ko) * 2022-12-12 2025-06-27 아벨로스테라퓨틱스 주식회사 치환된 헤테로고리 화합물 유도체 및 그의 약학적 용도
WO2024137979A2 (en) * 2022-12-23 2024-06-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Foxm1 inhibitors and their use in treating cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275611A1 (en) * 2008-11-20 2011-11-10 Jeffrey Michael Axten Chemical compounds
CN102947272A (zh) * 2010-05-12 2013-02-27 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的2-氨基吡啶衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US9481670B2 (en) * 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
US9604937B2 (en) * 2012-11-27 2017-03-28 Thomas Helledays Stiftelse For Medicinsk Forskning Pyrimidine-2,4-diamine derivatives for treatment of cancer
CN106794181A (zh) * 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275611A1 (en) * 2008-11-20 2011-11-10 Jeffrey Michael Axten Chemical compounds
CN102947272A (zh) * 2010-05-12 2013-02-27 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的2-氨基吡啶衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JESUS R. MEDINA 等: ""Structure-Based Design of Potent and Selective 3-Phosphoinositide-Dependent Kinase-1 (PDK1) Inhibitors"", 《J. MED. CHEM.》, vol. 54, 22 February 2011 (2011-02-22), pages 1871 - 1895 *

Also Published As

Publication number Publication date
EP4352049A4 (en) 2025-05-21
EP4352049A1 (en) 2024-04-17
WO2022260441A1 (en) 2022-12-15
KR20240006692A (ko) 2024-01-15
JP2024522201A (ja) 2024-06-11
GB202108249D0 (en) 2021-07-21
CA3216629A1 (en) 2022-12-15
US20240300936A1 (en) 2024-09-12
AU2022291332A1 (en) 2023-12-21
MX2023014784A (es) 2024-03-25

Similar Documents

Publication Publication Date Title
AU2017311645B2 (en) Pyridopyrimdinone CDK2/4/6 inhibitors
EP3612517B1 (en) Bicyclic compounds and their use in the treatment of cancer
CN115996929B (zh) 腺苷A2a受体的拮抗剂
EP2943485B1 (en) Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
JP2020519589A (ja) Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物
CN106458992B (zh) 吡啶基哌啶
AU2016287335B2 (en) TBK/IKKepsilon inhibitor compounds and uses thereof
TW201904959A (zh) 雜環化合物
CN117529476A (zh) 取代的1,2-二氨基杂环化合物衍生物的制备及其作为药剂的用途
EP4387963B1 (en) Phenyl- and pyridopyrazole derivatives as inhibitors of ddr1
CA3063809A1 (en) Compounds
WO2017045751A1 (en) Compounds as asic inhibitors and uses thereof
CA3119882A1 (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
CA3119886A1 (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
CN120359224A (zh) 取代的杂环化合物衍生物及其制药用途
JP2020537661A (ja) ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用
EA036060B1 (ru) Пиридопиримидиноновые ингибиторы cdk2/4/6
TW202545531A (zh) 氮—喹唑啉化合物之使用方法
HK40051446A (en) Phenoxy-pyridyl-pyrimidine compounds and methods of use
HK40021223B (en) Bicyclic compounds and their use in the treatment of cancer
HK1216316B (en) Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
HK40021417A (en) Heteroaryl pyridone and aza-pyridone amide compounds
HK1242303A1 (en) Heteroaryl compounds as irak inhibitors and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination